Novo Nordisk (NYSE:NVO) appears to be taking a no-holds-barred approach to becoming the number one weight-loss drugmaker in the US after it emerged that an ad for one of its key products was viewed nearly 2 billion times between June 3 and June 25, making it the third most-watched commercial during that period.
The Wall Street Journal, citing iSpot.tv, reported the Wegovy ad, titled 'Discover the Power', was shown 6,271 times and cost an estimated $42 million in national airtime.
This surge in advertising follows an FDA-approved update for Wegovy, broadening its usage to include cardiovascular benefits for obese or overweight individuals with heart disease.
Novo Nordisk (NYSE:NVO) is reportedly ramping up production and shipments to meet the growing demand. The company faces competition from compounded versions of its drugs and potential generics.